Key Points
- Insider Beth Hecht sold 25,000 Xeris Biopharma shares for $255,750 at an average price of $10.23 under a pre-arranged Rule 10b5-1 plan. She retained 1,086,130 shares after the sale.
- In its latest reported quarter, Xeris posted an EPS loss of $0.18, missing analysts’ estimate of $0.01, while revenue of $92.1 million topped the $90.12 million consensus.
- Analyst views are mixed but lean positive: MarketBeat’s consensus rating is “Moderate Buy,” with an average price target of $13.20.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Steven Pieper sold 5,000 shares of the company's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $51,150.00. Following the completion of the transaction, the insider owned 1,346,053 shares of the company's stock, valued at $13,770,122.19. The trade was a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Steven Pieper also recently made the following trade(s):
- On Thursday, October 1st, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $9.41, for a total value of $47,050.00.
- On Tuesday, September 1st, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $42,500.00.
- On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total transaction of $42,500.00.
Xeris Biopharma Stock Performance
Xeris Biopharma stock opened at $10.46 on Thursday. The firm has a fifty day simple moving average of $9.40 and a two-hundred day simple moving average of $7.55. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a twelve month low of $5.25 and a twelve month high of $11.41. The company has a market capitalization of $1.91 billion, a PE ratio of -95.09 and a beta of 0.61.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of $0.01 by ($0.19). The company had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. Research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.
Institutional Investors Weigh In On Xeris Biopharma
Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of Xeris Biopharma during the 2nd quarter valued at about $115,042,000. Legal & General Group Plc purchased a new stake in Xeris Biopharma in the second quarter worth about $15,941,000. Parkman Healthcare Partners LLC bought a new stake in Xeris Biopharma during the 2nd quarter valued at approximately $14,316,000. Bank of America Corp DE bought a new stake in Xeris Biopharma during the 2nd quarter valued at approximately $11,065,000. Finally, Vilga Financial Planning LLC purchased a new position in shares of Xeris Biopharma during the 3rd quarter worth approximately $10,134,000. 42.75% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
XERS has been the subject of a number of analyst reports. Weiss Ratings lowered Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Wall Street Zen raised shares of Xeris Biopharma from a "hold" rating to a "buy" rating in a research report on Saturday, September 19th. Leerink Partners raised their price target on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an "outperform" rating in a report on Thursday, September 10th. Finally, Barclays upped their price objective on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an "overweight" rating in a research note on Tuesday, October 6th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Xeris Biopharma has a consensus rating of "Moderate Buy" and an average target price of $13.20.
Get Our Latest Stock Report on Xeris Biopharma
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.
Xeris' commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing's syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
